Mariner LLC Has $313.15 Million Stock Position in AbbVie Inc. $ABBV

Mariner LLC lifted its stake in shares of AbbVie Inc. (NYSE:ABBV) by 2.3% during the fourth quarter, Holdings Channel.com reports. The firm owned 1,370,393 shares of the company’s stock after acquiring an additional 30,704 shares during the period. Mariner LLC’s holdings in AbbVie were worth $313,145,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Chelsea Counsel Co. acquired a new stake in AbbVie in the third quarter valued at approximately $26,000. Litman Gregory Wealth Management LLC acquired a new position in shares of AbbVie during the fourth quarter worth approximately $28,000. Westend Capital Management LLC bought a new position in shares of AbbVie in the 4th quarter worth $29,000. Texas Capital Bancshares Inc TX bought a new position in shares of AbbVie in the 3rd quarter worth $31,000. Finally, Legacy Wealth Managment LLC ID grew its position in AbbVie by 115.9% in the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock valued at $31,000 after purchasing an additional 73 shares during the period. 70.23% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have commented on ABBV shares. Evercore set a $235.00 price target on shares of AbbVie in a research note on Friday, May 15th. Morgan Stanley lifted their price objective on shares of AbbVie from $270.00 to $278.00 and gave the company an “overweight” rating in a report on Thursday, April 30th. Cantor Fitzgerald reiterated an “overweight” rating and set a $240.00 price objective on shares of AbbVie in a report on Thursday, April 30th. DZ Bank raised AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Thursday, April 30th. Finally, Wall Street Zen lowered AbbVie from a “strong-buy” rating to a “buy” rating in a report on Sunday, June 7th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, AbbVie presently has a consensus rating of “Moderate Buy” and an average price target of $253.43.

AbbVie Stock Performance

AbbVie stock opened at $227.54 on Monday. AbbVie Inc. has a fifty-two week low of $181.73 and a fifty-two week high of $244.81. The firm’s 50-day simple moving average is $211.05 and its 200 day simple moving average is $219.00. The stock has a market cap of $402.02 billion, a PE ratio of 112.09, a price-to-earnings-growth ratio of 0.70 and a beta of 0.32.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, beating the consensus estimate of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The firm had revenue of $15 billion during the quarter, compared to analyst estimates of $14.72 billion. During the same quarter last year, the business posted $2.46 EPS. The company’s revenue for the quarter was up 12.4% on a year-over-year basis. As a group, analysts predict that AbbVie Inc. will post 14.3 EPS for the current fiscal year.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie said nine-year CLL14 data showed venetoclax plus obinutuzumab delivered durable progression-free survival in previously untreated chronic lymphocytic leukemia, strengthening the case for the drug’s long-term commercial value. AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results
• Positive Sentiment: Investors are also focused on AbbVie’s broader pipeline and franchise strength, with commentary pointing to Skyrizi and Rinvoq continuing to drive revenue growth, which supports the company’s outlook beyond legacy Humira. Will Skyrizi & Rinvoq Continue to Drive AbbVie’s Topline Through 2026?
• Neutral Sentiment: Several market commentaries described AbbVie as a defensive, high-quality compounder, but noted the shares may not be cheap at current levels, which suggests valuation may temper upside even with strong fundamentals. AbbVie: A Defensive Compounder Worth Holding, But Not A Bargain Buy
• Negative Sentiment: One article highlighted regulatory risk around AbbVie’s fast-acting neurotoxin TrenibotE after an FDA complete response letter, which could delay a potential growth driver if development setbacks persist. FDA Issues Complete Response Letter for AbbVie’s Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.